Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT1 | P54687 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 6/20 | 0.50 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL892453 | 0.84 | TSHR (0.55) | BCAT1CYP3A4ALOX5TSHRIDO1 | |
| SCHEMBL9733160 | 0.78 | BCAT1 (1.00) | BCAT1IDO1GAAKAT6ASMN1; SMN2 | |
| SCHEMBL6362188 | 0.75 | ALOX5 (0.69) | BCAT1ALOX5GAASMN1; SMN2THRB | |
| SCHEMBL5708790 | 0.74 | ALDH1A1 (0.69) | CYP3A4ALOX5TSHRGAASMN1; SMN2 | |
| SCHEMBL8648511 | 0.73 | GAA (0.76) | CYP3A4ALOX5TSHRIDO1APOBEC3G | |
| SCHEMBL28032785 | 0.71 | CYP3A4 (0.60) | CYP3A4ALOX5TSHRIDO1GAA | |
| SCHEMBL10153739 | 0.71 | PKM (0.63) | PKMGAASMN1; SMN2LMNAKDM4E | |
| SCHEMBL27625271 | 0.70 | CYP3A4 (0.63) | CYP3A4ALOX5TSHRSMN1; SMN2 | |
| SCHEMBL588131 | 0.69 | ALOX5 (1.00) | CYP3A4ALOX5TSHRGAASMN1; SMN2 | |
| SCHEMBL425872 | 0.69 | ALOX5 (1.00) | CYP3A4ALOX5TSHRGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960686-B2 | Preparation and purification of antiviral disulfonic acid disodium salt | WYETH (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050038026-A1 | Preparation and purification of antiviral disulfonic acid disodium salt | WYETH (US) | 2005-02-17 | — | — | US | disclosed |
| US-6806366-B2 | SUCH AS 2-((4-(4-(4-(BIS-CARBAMOYLMETHYL-SULFAMOYL)-BENZYL) -6-CHLORO-(1,3,5)TRIAZIN-2-YLMETHYL)-BENZENESULFONYL)-CARBAMOYL METHYL-AMINO)ACETAMIDE; PRECIPITATION; CRYSTALLIZATION | WYETH | 2004-10-19 | — | — | US | disclosed |
| US-20020151548-A1 | Preparation and purification of antiviral disulfonic acid disodium salt | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-10-17 | — | — | US | disclosed |
| WO-2002062769-A2 | PREPARATION AND PURIFICATION OF ANTIVIRAL DISULFONIC ACID DISODIUM SALT | WYETH (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151548-A1 | Preparation and purification of antiviral disulfonic acid disodium salt | SAMHD1, DUS2, MPST | BCAT1 1081/4885CYP3A4 1311/4885ALOX5 4642/4885 |
| US-20050038026-A1 | Preparation and purification of antiviral disulfonic acid disodium salt | DUS2, SAMHD1, EIF2AK2 | BCAT1 1031/4885CYP3A4 1787/4885ALOX5 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.